Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas

Journal of Neuro-Oncology

Volumn 102, Issue 1, 2011, Pages 89-94

  Skiriute, Daina ^a   Tamasauskas, Sarunas ^a   Asmoniene, Virginija ^a   Saferis, Viktoras ^a   Skauminas, Kestutis ^a   Deltuva, Vytenis ^a   Tamasauskas, Arimantas ^a  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Gene expression; NDRG2; Primary meningioma; qRT PCR; Recurrent meningioma

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; NDRG2 GENE; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79952185609     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0291-9     Document Type: Article

References (28)

1. Perry A, Louis D, Scheithauer B, Budka H, von Deimling A (2007) Meningial tumors. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC Press, Lyon, pp 164-172
2. Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. The Lancet Neurol 5:1045-1054 (Pubitemid 44709980)
3. Simon MMD, Bostrom JPM, Hartmann CMD (2007) Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 60:787-798
4. Adegbite AB, Khan MI, Paine KWE, Tan LK (1983) The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58:51-56 (Pubitemid 13220947)
5. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455-1465 (Pubitemid 27528256)
6. Espinosa AB, Tabernero MD, Maillo A, Sayagues JM, Ciudad J, Merino M, Alguero MC, Lubombo AM, Sousa P et al (2006) The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res 12:772-780 (Pubitemid 43259857)
7. Maillo A, Orfao A, Espinosa AB, Sayagues JM, Merino M, Sousa P, Lara M, Tabernero MD (2007) Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro oncol 9:438-446
8. Mihaila D, Jankowski M, Gutierrez JA, Rosenblum ML, Newsham IF, Bogler O, Rempel SA (2003) Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 9:4443-4451 (Pubitemid 37248402)
9. Kim YJ, Ketter R, Henn W, Zang K, Steudel WI, Feiden W (2006) Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 449:529-538 (Pubitemid 44722321)
10. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestana A, Rey JA (1999) NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231-2239 (Pubitemid 29186924)
11. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC (2007) Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery 61:1048-1061
12. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM J, Menon AG (1995) Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55:4696-4701
13. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P (1997) Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94:14719-14724 (Pubitemid 28041440)
14. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A (2005) Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 65:7121-7126 (Pubitemid 41161241)
15. Yao L, Zhang J, Liu X (2008) NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochem Biophys Sin (Shanghai) 40:625-635 (Pubitemid 352009078)
16. Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, Wu Y, Ji S et al (2008) N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res 36:5335-5349
17. Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM et al (2007) Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 7:192
18. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123:2080-2086
19. Ildan F, Erman T, Göcer A, Tuna M, Bagdatoglu H, Cetinalp E, Burgut R (2007) Predicting the probability of meningioma recurrence in the preoperative and early postoperative period: a multivariate analysis in the midterm follow-up. Skull Base 17:157-172
20. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K (2000) Recurrence of meningiomas. Cancer 89:1102-1110
21. Ayerbe J, Lobato RD, de la Cruz J, Alday R, Rivas JJ, Gómez PA, Cabrera A (1999) Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) 141:921-932
22. Maillo A, Orfao A, Sayagues JM, Diaz P, Gomez-Moreta JA, Caballero M, Santamarta D, Santos-Briz A, Morales F, Tabernero MD (2003) New classification scheme for the prognostic strati- fication of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol 21:3285-3295 (Pubitemid 46606262)
23. Morokoff AP, Zauberman J, Black PM (2008) Surgery for convexity meningiomas. Neurosurgery 63:427-434
24. Carvalho L, Smirnov I, Baia G, Modrusan Z, Smith J, Jun P, Costello J, McDermott M, VandenBerg S, Lal A (2007) Molecular signatures define two main classes of meningiomas. Mol Cancer 6:64
25. Ozaki S, Nishizaki T, Ito H, Sasaki K (2004) Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol 41:167-174
26. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P (2005) Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114:249-256 (Pubitemid 40194294)
27. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG et al (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 68:4210-4220
28. Schiffer D, Ghimenti C, Fiano V (2005) Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol 73:125-130 (Pubitemid 40974032)